299 related articles for article (PubMed ID: 20838799)
1. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.
Goker-Alpan O; Stubblefield BK; Giasson BI; Sidransky E
Acta Neuropathol; 2010 Nov; 120(5):641-9. PubMed ID: 20838799
[TBL] [Abstract][Full Text] [Related]
2. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
[TBL] [Abstract][Full Text] [Related]
3. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
5. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.
DePaolo J; Goker-Alpan O; Samaddar T; Lopez G; Sidransky E
Mov Disord; 2009 Aug; 24(11):1571-8. PubMed ID: 19425057
[TBL] [Abstract][Full Text] [Related]
6. Parkinsonism, dementia and glucocerebrosidase mutations.
Peall K; Robertson NP
J Neurol; 2013 May; 260(5):1441-4. PubMed ID: 23620067
[No Abstract] [Full Text] [Related]
7. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.
Goker-Alpan O; Giasson BI; Eblan MJ; Nguyen J; Hurtig HI; Lee VM; Trojanowski JQ; Sidransky E
Neurology; 2006 Sep; 67(5):908-10. PubMed ID: 16790605
[TBL] [Abstract][Full Text] [Related]
8. TIGAR inclusion pathology is specific for Lewy body diseases.
López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
[TBL] [Abstract][Full Text] [Related]
9. Exploring the link between glucocerebrosidase mutations and parkinsonism.
Westbroek W; Gustafson AM; Sidransky E
Trends Mol Med; 2011 Sep; 17(9):485-93. PubMed ID: 21723784
[TBL] [Abstract][Full Text] [Related]
10. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
11. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
Tayebi N; Walker J; Stubblefield B; Orvisky E; LaMarca ME; Wong K; Rosenbaum H; Schiffmann R; Bembi B; Sidransky E
Mol Genet Metab; 2003 Jun; 79(2):104-9. PubMed ID: 12809640
[TBL] [Abstract][Full Text] [Related]
12. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
Sardi SP; Clarke J; Viel C; Chan M; Tamsett TJ; Treleaven CM; Bu J; Sweet L; Passini MA; Dodge JC; Yu WH; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3537-42. PubMed ID: 23297226
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
Zhou W; Milder JB; Freed CR
J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
[TBL] [Abstract][Full Text] [Related]
14. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
[TBL] [Abstract][Full Text] [Related]
15. GBA1-associated parkinsonism: new insights and therapeutic opportunities.
Ryan E; Seehra G; Sharma P; Sidransky E
Curr Opin Neurol; 2019 Aug; 32(4):589-596. PubMed ID: 31188151
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
17. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
[TBL] [Abstract][Full Text] [Related]
18. Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations.
Choi JH; Stubblefield B; Cookson MR; Goldin E; Velayati A; Tayebi N; Sidransky E
Mol Genet Metab; 2011; 104(1-2):185-8. PubMed ID: 21742527
[TBL] [Abstract][Full Text] [Related]
19. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.
Schlossmacher MG; Frosch MP; Gai WP; Medina M; Sharma N; Forno L; Ochiishi T; Shimura H; Sharon R; Hattori N; Langston JW; Mizuno Y; Hyman BT; Selkoe DJ; Kosik KS
Am J Pathol; 2002 May; 160(5):1655-67. PubMed ID: 12000718
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase and its relevance to Parkinson disease.
Do J; McKinney C; Sharma P; Sidransky E
Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
